| Active Not Recruiting | Belantamab Mafodotin and Lenalidomide for the Treatment of Multiple Myeloma in Patients With Minimal Residual NCT04876248 | Roswell Park Cancer Institute | Phase 2 |
| Withdrawn | Radioimmunotherapy (211At-OKT10-B10) and Chemotherapy (Melphalan) Before Stem Cell Transplantation for the Tre NCT04466475 | Fred Hutchinson Cancer Center | Phase 1 |
| Recruiting | Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant i NCT05561387 | SWOG Cancer Research Network | Phase 3 |
| Recruiting | Imaging Study of [89Zr]DFO-YS5 for Detecting CD46 Positive Malignancy in Multiple Myeloma NCT05892393 | Robert Flavell, MD, PhD | Phase 1 |
| Active Not Recruiting | International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clini NCT05669989 | Sanofi | Phase 2 |
| Completed | Evaluation of Comprehensive Geriatric Assessment and Laboratory Biomarkers in Elderly Patients With Multiple M NCT05918185 | Mayo Clinic | — |
| Completed | Home Based Daratumumab Administration for Patients With Multiple Myeloma NCT05511428 | Thomas Jefferson University | Phase 4 |
| Suspended | Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbet NCT05400122 | David Wald | Phase 1 |
| Active Not Recruiting | Iberdomide, Daratumumab, Bortezomib, and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma, IDEA NCT05392946 | Mayo Clinic | Phase 1 / Phase 2 |
| Recruiting | Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma NCT05208307 | Emory University | Phase 2 |
| Recruiting | Non-chemotherapeutic Interventions for the Improvement of Quality of Life and Immune Function in Patients With NCT05312255 | Roswell Park Cancer Institute | N/A |
| Terminated | Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) in Combination With a Corticosteroid Drug ( NCT05288062 | Mayo Clinic | Phase 2 |
| Unknown | Venetoclax in Combination With Non-myeloablative Conditioning Allogeneic Haematopoietic Stem Cell Transplantat NCT05005299 | Melbourne Health | Phase 1 |
| Unknown | Loratadine for the Reduction of G-CSF Induced Bone Pain in Patients With Multiple Myeloma Undergoing Stem Cell NCT04211259 | Rutgers, The State University of New Jersey | EARLY_Phase 1 |
| Withdrawn | Pembrolizumab as Salvage Therapy for the Treatment of Multiple Myeloma in Patients Progressing on CAR-T Cell T NCT05204160 | Emory University | Phase 2 |
| Completed | Chaplain-Delivered Compassion Meditation to Improve Quality of Life in Patients Receiving a Stem Cell Transpla NCT05274763 | Emory University | N/A |
| Terminated | Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutatio NCT05153330 | Biomea Fusion Inc. | Phase 1 |
| Completed | Telehealth Exercise Intervention to Improve Physical Function and Frailty in Multiple Myeloma Survivors NCT05142371 | City of Hope Medical Center | N/A |
| Active Not Recruiting | SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer NCT04977024 | GeoVax, Inc. | Phase 2 |
| Active Not Recruiting | Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma NCT04782687 | US Oncology Research | Phase 2 |
| Completed | Understanding the Risk of Blood Clots and Bleeding in Patients With Hematological Malignancies, HAT Study NCT05053100 | Mayo Clinic | — |
| Completed | Geriatric Optimization Plan to Improve Survival in Older Adult Allogeneic Hematopoietic Cell Transplant Candid NCT05972577 | Ohio State University Comprehensive Cancer Center | N/A |
| Terminated | Belantamab Mafodotin, Lenalidomide, and Daratumumab for the Treatment of Relapsed, Refractory, or Previously U NCT04892264 | Mayo Clinic | Phase 1 |
| Terminated | Xisomab 3G3 for the Prevention of Catheter-Associated Thrombosis in Patients With Cancer Receiving Chemotherap NCT04465760 | OHSU Knight Cancer Institute | Phase 2 |
| Recruiting | Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Tri NCT04566328 | ECOG-ACRIN Cancer Research Group | Phase 3 |
| Active Not Recruiting | Cardiovascular Reserve Evaluation in Survivors of Transplant, CREST Study NCT04537871 | City of Hope Medical Center | — |
| Terminated | Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients With Hematologic Malig NCT03272633 | Rutgers, The State University of New Jersey | EARLY_Phase 1 |
| Completed | Fermented Milk Supplementation on Symptoms of Disease and Treatment in Patients With Multiple Myeloma NCT04530812 | Roswell Park Cancer Institute | N/A |
| Active Not Recruiting | A Prospective, Non-interventional, Multinational, Observational Study With Isatuximab in Patients With Relapse NCT04458831 | Sanofi | — |
| Active Not Recruiting | Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma NCT04270409 | Sanofi | Phase 3 |
| Terminated | Daratumumab-Based Therapy for the Treatment of Newly Diagnosed Multiple Myeloma With Kidney Failure NCT04352205 | Emory University | Phase 2 |
| Completed | DISCO Application for the Improvement of Financial Outcomes in Patients With Hematologic Cancer NCT04282343 | Barbara Ann Karmanos Cancer Institute | N/A |
| Terminated | Enhancing Anti--Tetanus Vaccine Response After Autologous Stem Cell Transplantation NCT02700841 | University of Nebraska | Phase 2 |
| Recruiting | Neurocognitive Outcomes After Whole Brain Radiation Therapy for Hematologic Malignancies NCT05011045 | M.D. Anderson Cancer Center | — |
| Active Not Recruiting | Stopping Maintenance Therapy in People With Multiple Myeloma in MRD-Negative Remission NCT04221178 | Memorial Sloan Kettering Cancer Center | — |
| Completed | Strength Training in Improving Pain and Quality of Life in Patients With Multiple Myeloma NCT03793907 | Roswell Park Cancer Institute | N/A |
| Terminated | Cryocompression Therapy for Peripheral Neuropathy in Patients With Multiple Myeloma NCT03870451 | Wake Forest University Health Sciences | N/A |
| Completed | Exercise Prescription for the Improvement of Quality of Life in Elderly Patients With Multiple Myeloma NCT04100044 | Thomas Jefferson University | N/A |
| Completed | Melphalan Hydrochloride in Treating Participants With Newly-Diagnosed Multiple Myeloma Undergoing Donor Stem C NCT03417284 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Completed | First-in-human Single Agent Study of SAR442085 in Relapsed or Refractory Multiple Myeloma NCT04000282 | Sanofi | Phase 1 |
| Active Not Recruiting | Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell Transplant NCT03622788 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Active Not Recruiting | Daratumumab After Stem Cell Transplant in Treating Patients With Multiple Myeloma NCT03346135 | City of Hope Medical Center | Phase 2 |
| Active Not Recruiting | Daratumumab, Ixazomib, & Dexamethasone or Daratumumab, Bortezomib, & Dexamethasone in Patients With Newly Diag NCT03942224 | Emory University | Phase 2 |
| Completed | Assessment of Financial Difficulty in Participants with Chronic Lymphocytic Leukemia and Multiple Myeloma NCT03870633 | Alliance for Clinical Trials in Oncology | — |
| Recruiting | Low-Dose Radiotherapy in Treating Painful Bone Metastases in Patients With Multiple Myeloma NCT03858205 | University of Southern California | N/A |
| Active Not Recruiting | Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With High-Risk Multiple Myeloma NCT03756896 | Emory University | Phase 2 |
| Completed | Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803 NCT02890758 | Brenda Cooper, MD | Phase 1 |
| Completed | Carfilzomib in Combination With Daratumumab, Lenalidomide and Dexamethasone in Transplant-ineligible NDMM Pati NCT04065789 | Tel-Aviv Sourasky Medical Center | Phase 2 |
| Completed | Daratumumab in Treating Transplant-Eligible Patients With Multiple Myeloma NCT03477539 | Mayo Clinic | Phase 2 |
| Terminated | Allogeneic Stem Cell Transplantation for Multiple Myeloma and Myelofibrosis NCT03303950 | University of Utah | Phase 2 |
| Completed | Copper 64Cu-DOTA-Daratumumab Positron Emission Tomography in Diagnosing Patients With Relapsed Multiple Myelom NCT03311828 | City of Hope Medical Center | Phase 1 |
| Completed | Isatuximab in Combination With Cemiplimab in Relapsed/Refractory Multiple Myeloma (RRMM) Patients NCT03194867 | Sanofi | Phase 1 / Phase 2 |
| Withdrawn | Melphalan, Total Marrow Irradiation, and Autologous Stem Cell Transplantation in Treating Patients With High-R NCT03100877 | City of Hope Medical Center | Phase 1 / Phase 2 |
| Active Not Recruiting | A Study to Investigate the Clinical Benefit of Isatuximab in Combination With Bortezomib, Lenalidomide and Dex NCT03319667 | Sanofi | Phase 3 |
| Terminated | Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Pa NCT03333486 | Roswell Park Cancer Institute | Phase 2 |
| Completed | Multinational Clinical Study Comparing Isatuximab, Carfilzomib And Dexamethasone To Carfilzomib And Dexamethas NCT03275285 | Sanofi | Phase 3 |
| Completed | Stem Cell Transplant With or Without Tbo-filgrastim in Treating Patients With Multiple Myeloma or Non-Hodgkin NCT03317899 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Phase 2 |
| Active Not Recruiting | Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus H NCT03192397 | Roswell Park Cancer Institute | Phase 1 / Phase 2 |
| Completed | Dysregulation of Glutamine Activity in the Pathogenesis of Multiple Myeloma NCT03119883 | Mayo Clinic | N/A |
| Active Not Recruiting | Decision Aid Website in Helping to Make Decisions About Fertility in Participants With Cancer NCT03141437 | M.D. Anderson Cancer Center | N/A |
| Completed | Ixazomib Citrate, Lenalidomide, Dexamethasone, and Daratumumab in Treating Patients With Newly Diagnosed Multi NCT03012880 | Mayo Clinic | Phase 2 |
| Active Not Recruiting | SVN53-67/M57-KLH Peptide Vaccine in Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalido NCT02334865 | Roswell Park Cancer Institute | Phase 1 |
| Completed | Daratumumab in Treating Patients With Multiple Myeloma NCT02944565 | Ohio State University Comprehensive Cancer Center | Phase 2 |
| Completed | Evaluating Effectiveness of Powered Drill Bone Marrow Biopsy NCT03078452 | Emory University | N/A |
| Completed | Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies NCT02960646 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Biobehavioral Intervention to Enhance Hematopoietic Stem Cell Transplant Recovery NCT02955043 | University of Wisconsin, Madison | N/A |
| Completed | Multinational Clinical Study Comparing Isatuximab, Pomalidomide, and Dexamethasone to Pomalidomide and Dexamet NCT02990338 | Sanofi | Phase 3 |
| Completed | Pembrolizumab, Lenalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma Elig NCT02880228 | Mayo Clinic | Phase 2 |
| Completed | Lenalidomide and Dexamethasone With or Without Anakinra in Treating Patients With Early Stage Multiple Myeloma NCT02492750 | Mayo Clinic | Phase 1 |
| Completed | Alternating Ixazomib Citrate and Lenalidomide as Maintenance Therapy After Stem Cell Transplant in Treating Pa NCT02619682 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Pomalidomide, Ixazomib Citrate, and Dexamethasone in Treating Patients With Previously Treated Multiple Myelom NCT02547662 | Mayo Clinic | Phase 2 |
| Completed | Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients Wi NCT02566304 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Phase 2 |
| Completed | Study of Isatuximab Combined With Bortezomib + Cyclophosphamide + Dexamethasone (VCD) and Bortezomib + Lenalid NCT02513186 | Sanofi | Phase 1 |
| Completed | A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Isatuximab in Patients With Multiple Myeloma NCT02514668 | Sanofi | Phase 1 |
| Active Not Recruiting | Lenalidomide Maintenance in Plasma Cell Myeloma NCT02538198 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Completed | SAR650984, Pomalidomide and Dexamethasone in Combination in RRMM Patients NCT02283775 | Sanofi | Phase 1 |
| Active Not Recruiting | Elotuzumab and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myel NCT02420860 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Lenalidomide With or Without Ixazomib Citrate and Dexamethasone in Treating Patients With Residual Multiple My NCT02389517 | University of Chicago | Phase 2 |
| Completed | MLN9708 (Ixazomib) in Combination With Panobinostat and Dexamethasone in Multiple Myeloma NCT02057640 | Jason Valent | Phase 1 / Phase 2 |
| Active Not Recruiting | Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multip NCT01863550 | ECOG-ACRIN Cancer Research Group | Phase 3 |
| Completed | Lenalidomide and Ipilimumab After Stem Cell Transplant in Treating Patients With Hematologic or Lymphoid Malig NCT01919619 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Ixazomib With Cyclophosphamide and Dexamethasone in Patients With Previously Untreated Symptomatic Multiple My NCT01864018 | Mayo Clinic | Phase 1 / Phase 2 |
| Completed | Umbilical Cord Blood-Derived Natural Killer Cells, Elotuzumab, Lenalidomide, and High Dose Melphalan, Followed NCT01729091 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | SAR650984 (Isatuximab), Lenalidomide, and Dexamethasone in Combination in RRMM Patients NCT01749969 | Sanofi | Phase 1 |
| Completed | Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic Malignancies NCT01760655 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Phase 2 |
| Completed | Ixazomib Citrate and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multipl NCT01718743 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Collection of Transplant Stem Cells for Plasma Cell Myeloma NCT01547806 | National Cancer Institute (NCI) | Phase 2 |
| Completed | 90 Y-BC8-DOTA Monoclonal Antibody, Fludarabine Phosphate, and Total-Body Irradiation Followed by Donor Periphe NCT01503242 | Fred Hutchinson Cancer Center | Phase 1 |
| Withdrawn | S0833, Bortezomib, Thalidomide, Lenalidomide, Combination Chemotherapy, and Autologous Stem Cell Transplant in NCT01055301 | SWOG Cancer Research Network | Phase 2 |
| Completed | Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patient NCT01251575 | Fred Hutchinson Cancer Center | Phase 2 |
| Terminated | Melphalan and Bortezomib Prior to Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma NCT02353572 | University of Colorado, Denver | Phase 1 / Phase 2 |
| Completed | Dalteparin in Preventing DVT in Participants With Cancer NCT00525057 | M.D. Anderson Cancer Center | N/A |
| Completed | Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patient NCT00719888 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | S0115, High-Dose Melphalan and Autologous Peripheral Stem Cell Transplantation in Treating Patients With Multi NCT00064337 | SWOG Cancer Research Network | Phase 2 |
| Completed | Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treatin NCT00075478 | Fred Hutchinson Cancer Center | Phase 3 |
| Completed | Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Ce NCT00096161 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | S0120, Studying Blood and Bone Marrow Samples From Patients With Monoclonal Gammopathy of Undetermined Signifi NCT00900263 | SWOG Cancer Research Network | — |